Thursday, February 6, 2014

Diabetes in China:
Canadian Biotech Aims to Make a Difference

WINNIPEG,
Manitoba, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Diabetes
and heart disease are health scourges that are not exclusive to North America. They are killing
millions around the world every year. Earlier and earlier detection and
treatment is the only way to mitigate the numbers suffering or lost.
Fortunately, small biotech companies are aggressively pursuing amazing
technologies, including early diagnostic and risk assessment tests, in an effort
to slow or eradicate these devastating public health challenges, whether found
in Washington,
Toronto,
London,
Beijing or
Capetown. These smaller biotech companies like Canadian based Miraculins Inc (TSX-V:MOM), are
doing much of the most exciting work in diagnostics. While the key is obviously
the technology, the point for investors is to find those opportunities that
reach the largest markets, have the best efficacy, are easy to use and readily
available at low cost.

Based in Winnipeg, Miraculins recently announced a term sheet for an
exclusive distribution deal for its Scout DS® Non-Invasive Diabetes
Screening test with China's Cachet Pharmaceutical, a
$700 million market cap company. The Canadian-based biotechnology
company develops and commercializes diagnostic and risk assessment technologies
through licensing and/or acquisition. The Scout DS® is the world's
first non-invasive and highly sensitive test designed to measure diabetes
related biomarkers in the skin. It does not require a blood draw or fasting and
generates a result in as little as 80 seconds. The Scout DS® uses
visible light to measure the optical signature of fluorescent biomarkers in the
skin, the accumulation of which are accelerated by abnormal blood sugar levels
and oxidative stress. Once cleared by the CFDA, Cachet's minimum orders over the
5-year term could represent in excess of $90 million USD in
revenue to Miraculins.
Upfront fees paid by Cachet to Miraculins could amount to $500,000
USD.

The World Health Organization states that Diabetes will be the
7th leading cause of death by 2030. One has to merely analyze the
western lifestyle to realize the growth of the disease in the US alone. That
said 80% of diabetes occurs in low and middle-income countries. The growth of
affluence and sedentary lifestyle in China, for example, has caused the growth of the
disease to become rampant, where there was virtually no Type 2 diabetes a decade
ago. Just as in the US and western nations, the rapid growth of the disease is
straining health care. With 11.6% of Chinese having diabetes versus 11.3% in the
US, new tests and treatments are critical. Those numbers will only get
worse.
"Given the need for this test in China, we are confident that on the agreement's
expected conclusion within 90 days, this deal will be transformative for Miraculins and our shareholders.
The marketing and sales of our test by Cachet puts us firmly on the global stage
as we move towards becoming a world-class diagnostic and risk assessment
leader," states Christopher Moreau, President and CEO of Miraculins.

Scout DS® has been cleared for sale in Canada and the EU, and Miraculins has recently filed
pre-submission documentation with the USFDA (United States Food and Drug
Administration) towards securing Scout DS® marketing clearance
in the United
States.
In the case of heart disease, the leading cause of death globally (48%), the
earlier it is detected, the greater the chance of survival. Think in terms of a
non-invasive cholesterol test you can take at a local pharmacy to assess the
risk of coronary artery or heart disease. And have the results in 5 minutes.

"Most people don't realize that there is measurable cholesterol present in
skin," stated Moreau. "While a test such as our PreVu®
skin cholesterol test does not replace blood work, it is a low cost, first line
indicator, much like the ubiquitous high blood pressure machines located in
pharmacies in Canada and around the world."

As stated in the BC Medical Journal in December
2012: "The PreVu Point of Care (POC) test
identifies individuals who may be at a higher, hidden risk of coronary artery
disease. The POC test may become a tool in the prevention of the critical first
incident; patients whose scores are elevated in the POC test will be advised to
seek advice from their physician." Miraculins has also been
in a collaborative development program with diagnostic giant Alere Inc. and has
pursued technology that identifies the presence of the biomarker Endoglin as a
promising, potential early indicator of Preeclampsia, which costs the world
health system $3 billion a year.
The global diagnostic market generates revenues of $30
billion; $11 billion in the US. One merely has
to pay cursory attention to the media to know that figure will, unfortunately,
rise significantly as the global population grows and ages.

In a world that can't have too many diagnostic and risk assessment tests,
those that provide ease of use, low cost and substantive results will have the
greatest impact on patients. Investors who want worthwhile early stage biotech
would do well to consider companies such as Miraculins.
One gets the sense that CEO Chris Moreau and his team care
as much about patients as shareholders. And that's the way it should be.

"We believe strongly in our technologies, in their capacity to impact
patients in need worldwide, and we believe in the corresponding potential of our
company to build and achieve significant value for shareholders along the way,"
Moreau added.

Legal Disclaimer/Disclosure:
A fee has been paid for the production and distribution of this Report. This
document is not and should not be construed as an offer to sell or the
solicitation of an offer to purchase or subscribe for any investment. No
information in this article should be construed as individualized investment
advice. A licensed financial advisor should be consulted prior to making any
investment decision. Financial Press makes no guarantee,
representation or warranty and accepts no responsibility or liability as to its
accuracy or completeness. Expressions of opinion are those of the author's only
and are subject to change without notice. Financial Press assumes no
warranty, liability or guarantee for the current relevance, correctness or
completeness of any information provided within this article and will not be
held liable for the consequence of reliance upon any opinion or statement
contained herein or any omission. Furthermore, we assume no liability for any
direct or indirect loss or damage or, in particular, for lost profit, which you
may incur as a result of the use and existence of the information, provided
within this article.
Also, please note that republishing of this article in its entirety is
permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.
CONTACT: Miraculins Inc.
204-453-1408 204-453-1546 (FAX) info@miraculins.com www.miraculins.com

EXPECT A BIG YEAR AHEAD AS WE ENTER THE SUPERBULL OF MARKET PHASES Throughout the year I evaluate where I am investing for the following 6...

THE MARKETS MOVE FAST

Follow by Email

*PLEASE READ THE CONDITIONS OF USE FOR THIS BLOG!

CONTENT POSTED ON THIS BLOG DOES NOT CONSTITUTE A BUY OR SELL RECOMMENDATION. MANY OF THE COMPANIES PROFILED HERE I AM NOT INVESTED IN AND DO NOT INTEND TO INVEST IN. THESE ARE MERELY MY THOUGHTS ON MARKET CONDITIONS AND STOCK VALUATIONS. INVESTING IN THE STOCK MARKET CAN BE VERY RISKY AND YOU SHOULD ALWAYS CONSULT AN INVESTMENT PROFESSIONAL BEFORE MAKING ANY DECISIONS. ULTIMATELY YOU ARE RESPONSIBLE FOR CONDUCTING YOUR OWN DUE DILIGENCE AND PROTECTING YOUR MONEY.

PLEASE NOTE: thetradersdigest.blogspot.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this email / blog / website viewing or using you agree to hold thetradersdigest.blogspot.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.Thetradersdigest.blogspot.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and thetradersdigest.blogspot.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead thetradersdigest.blogspot.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review Sedar, SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. thetradersdigest.blogspot.com is compliant with the Can Spam Act of 2003.

Thetradersdigest.blogspot.com does not offer such advice or analysis, and thetradersdigest.blogspot.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

Thetradersdigest.blogspot.com is often times compensated to feature certain companies. These third parties may have shares and may liquidate, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, thetradersdigest.blogspot.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, thetradersdigest.blogspot.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. thetradersdigest.blogspot.com is not responsible for any claims made by the companies advertised herein, nor is thetradersdigest.blogspot.com responsible for any other promotional firm, its program or its structure.

Third Party Web Sites and Information: thetradersdigest.blogspot.com and newsletter may provide hyperlinks to third party websites or access to third party content. thetradersdigest.blogspot.com does not control, endorse, or guarantee content found in such sites. You agree that thetradersdigest.blogspot.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that thetradersdigest.blogspot.com, Inc. shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.